早期上皮性卵巢癌化学治疗现状与思考

doi:10.3877/cma.j.issn.1673-5250.2020.01.003

中华妇幼临床医学杂志(电子版) ›› 2020, Vol. 16 ›› Issue (01) : 16 -22. doi: 10.3877/cma.j.issn.1673-5250.2020.01.003

所属专题：文献；

述评

早期上皮性卵巢癌化学治疗现状与思考

龚照林¹, 李克敏¹, 尹如铁¹^,^†(

)

^1. 四川大学华西第二医院妇产科、出生缺陷与相关妇儿疾病教育部重点实验室，成都　610041

收稿日期:2019-12-01 修回日期:2020-01-11 出版日期:2020-02-01
通信作者: 尹如铁

Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer

Zhaolin Gong¹, Kemin Li¹, Rutie Yin¹^,^†()

^1. Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China

Received:2019-12-01 Revised:2020-01-11 Published:2020-02-01
Corresponding author: Rutie Yin
About author:
Corresponding author: Yin Rutie, Email: yrtt2013@163.com
Supported by:
Science and Technology Plan Project of Science and Technology Department of Sichuan Province(19ZDYF2754)

全文 ( ) 下载PDF ( ) 导出引用

引用本文：

龚照林, 李克敏, 尹如铁. 早期上皮性卵巢癌化学治疗现状与思考[J/OL]. 中华妇幼临床医学杂志(电子版), 2020, 16(01): 16-22.

Zhaolin Gong, Kemin Li, Rutie Yin. Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer[J/OL]. Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition), 2020, 16(01): 16-22.

目前卵巢癌患者的死亡率，高居女性生殖系统恶性肿瘤患者的首位。卵巢癌的组织病理学类型复杂，其中上皮性卵巢癌(EOC)最为常见。但是，临床诊断的早期上皮性卵巢癌(EEOC)患者，仅占全部被诊断卵巢癌患者的30%。全面分期手术后，对高危EEOC患者的辅助化疗，是EEOC患者的标准治疗策略，但是辅助化疗方面，迄今尚有很多值得探讨的问题。笔者拟就EEOC患者术后辅助化疗研究现状，如患者化疗获益、化疗方案和化疗最佳时机选择、化疗疗程与淋巴切除问题的研究现状进行阐述，旨在为本病的规范化临床治疗提供参考。

关键词: 卵巢肿瘤, 上皮样细胞, 癌，子宫内膜样, 上皮性卵巢肿瘤，早期, 腺癌，透明细胞, 抗肿瘤联合化疗方案, 女(雌)性

Ovarian cancer is one of the most deadly malignancies of female reproductive system, with complex pathological types. The epithelial ovarian cancer (EOC) is the most common pathological type in ovarian cancer, but early-stage epithelial ovarian cancer (EEOC) only accounts for 30% in all diagnosed ovarian cancer. Adjuvant chemotherapy is the standard treatment strategy for high-risk EEOC patients after comprehensive staging surgery, but many issues are still worthy of discussion in adjuvant chemotherapy. We intend to clarify the current research status of postoperative adjuvant chemotherapy in patients with EEOC, such as the benefits of chemotherapy, the choice of chemotherapy regimen and the best timing for chemotherapy, the duration of chemotherapy and lymphadenectomy. We expect that this review can help providing references for standardized treatment of this disease.

Key words: Ovarian neoplasms, Epithelioid cells, Carcinoma, endometrioid, Epithelial ovarian neoplasms, early stage, Adenocarcinoma, clear cell, Antineoplastic combined chemotherapy protocols, Female

[1]	De Vita V, Hellman S, Rosenberg SA. Cancer: principles and practice of oncology[J]. J Am Med Association, 2001, 286: 1904-1905. DOI: 10.1001/jama.286.15.1904.
[2]	Young RC, Walton LA, Ellenberg SS, et al. Adjuvant therapy in stageⅠ and stage Ⅱ epithelial ovarian cancer results of two prospective randomized trials[J]. NEJM, 1990, 322(15): 1021-1027. DOI: 10.1056/NEJM199004123221501.
[3]	Chan JK, Tian C, Monk BJ, et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study[J]. Cancer, 2008, 112(10): 2202-2210. DOI: 10.1002/cncr.23390.
[4]	Colombo N, Guthrie D, Chiari S, et al. International Collaborative Ovarian Neoplasm trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer[J]. J Natl Cancer Inst, 2003, 95(2): 125-132. DOI: 10.1093/jnci/95.2.125.
[5]	Trimbos JB, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial[J]. J Natl Cancer Inst, 2003, 95(2): 113-125. DOI: 10.1093/jnci/95.2.113.
[6]	Lawrie TA, Winter-Roach BA, Heus P, et al. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2015, (12): CD004706. DOI: 10.1002/14651858.CD004706.pub5.
[7]	Trimbos JB, Parmar M, Vergote I, et al. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase Ⅲ trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma[J]. J Natl Cancer Inst, 2003, 95(2): 105-112. DOI：10.1093/jnci/95.2.105.
[8]	Tropé C, Kaern J, Hogberg T, et al. Randomized study on adjuvant chemotherapy in stage Ⅰhigh-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument[J]. Ann Oncol, 2000, 11(3): 281-288. DOI: 10.1023/a：1008399414923.
[9]	Bolis G, Colombo N, Pecorelli S, et al. Adjuvant treatment for early epithelial ovarian cancer: results of two randomised clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P)[J]. Ann Oncol, 1995, 6(9): 887-893. DOI: 10.1093/oxfordjournals.annonc.a059355.
[10]	Collinson F, Qian W, Fossati R, et al. Optimal treatment of early-stage ovarian cancer[J]. Ann Oncol, 2014, 25(6): 1165-1171. DOI: 10.1093/annonc/mdu116.
[11]	Adams G, Zekri J, Wong H, et al. Platinum-based adjuvant chemotherapy for early-stage epithelial ovarian cancer: single or combination chemotherapy？[J]. BJOG, 2010, 117(12): 1459-1467. DOI: 10.1111/j.1471-0528.2010.02635.x.
[12]	Kolb BA, Buller RE, Connor JP, et al. Effects of early postoperative chemotherapy on wound healing[J]. Obstet Gynecol, 1992, 79(6): 988-992.
[13]	Wright J, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival[J]. Br J Cancer, 2008, 98(7): 1197-1203. DOI: 10.1038/sj.bjc.6604298.
[14]	Tewari KS, Java JJ, Eskander RN, et al. Early initiation of chemotherapy following complete resection of advanced ovarian cancer associated with improved survival: NRG Oncology/Gynecologic Oncology Group study[J]. Ann Oncol, 2016, 27(1): 114-121. DOI: 10.1093/annonc/mdv500.
[15]	Dinkelspiel HE, Tergas AI, Zimmerman LA, et al. Use and duration of chemotherapy and its impact on survival in early-stage ovarian cancer[J]. Gynecol Oncol, 2015, 137(2): 203-209. DOI: 10.1016/j.ygyno.2015.02.013.
[16]	Chatterjee S, Chen L, Tergas AI, et al. Utilization and outcomes of chemotherapy in women with intermediate-risk, early-stage ovarian cancer[J]. Obste Gynecol, 2016, 127(6): 992-1002. DOI: 10.1097/AOG.0000000000001404.
[17]	Winter-Roach BA, Kitchener HC, Lawrie TA. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer[J]. Cochrane Database Syst Rev, 2012, (3): CD004706. DOI: 10.1002/14651858.CD004706.pub4.
[18]	Hogen L, Brar H, Covens A, et al. Is adjuvant chemotherapy beneficial for surgical stage Ⅰ ovarian clear cell carcinoma？[J]. Gynecol Oncol, 2017, 147(1): 54-60. DOI: 10.1016/j.ygyno.2017.07.128.
[19]	Takada T, Iwase H, Iitsuka C, et al. Adjuvant chemotherapy for stage Ⅰ clear cell carcinoma of the ovary an analysis of fully staged patients[J]. Int J Gynecol Cancer, 2012, 22(4): 573-578. DOI: 10.1097/IGC.0b013e31823fd413.
[20]	Mizuno M, Kajiyama H, Shibata K, et al. Adjuvant chemotherapy for stage Ⅰ ovarian clear cell carcinoma is it necessary for stage Ⅰ_A？[J]. Int J Gynecol Cancer, 2012, 22(7): 1143-1149. DOI: 10.1097/IGC.0b013e31825c7cbe.
[21]	Oseledchyk A, Leitao MM Jr, Konner J, et al. Adjuvant chemotherapy in patients with stage Ⅰ endometrioid or clear cell ovarian cancer in the platinum era: a surveillance, epidemiology, and end results cohort study, 2000-2013[J]. Ann Oncol，2017, 28(12): 2985-2993. DOI: 10.1093/annonc/mdx525.
[22]	Timmers PJ, Zwinderman AH, Teodorovic I, et al. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial[J]. Int J Gynecol Cancer, 2009, 19(1): 88-93. DOI: 10.1111/IGC.0b013e3181991546.
[23]	Nasioudis D, Haggerty AF, Giuntoli RL, et al. Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma[J]. Gynecol Oncol, 2019, 154(2): 302-307. DOI: 10.1016/j.ygyno.2019.05.009.
[24]	Chan JK, Java JJ, Fuh K, et al. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients: an analysis of NRG Oncology/Gynecologic Oncology Group trials[J]. Gynecol Oncol, 2016, 143(3): 490-495. DOI: 10.1016/j.ygyno.2016.09.015.
[25]	Young RC, Brady MF, Nieberg RK, et al. Adjuvant treatment for early ovarian cancer: a randomized phase Ⅲ trial of intraperitoneal 32P or intravenous cyclophosphamide and cisplatin--a gynecologic oncology group study[J]. J Clin Oncol, 2003, 21(23): 4350-4355. DOI: 10.1200/JCO.2003.02.154.
[26]	Bell J, Brady MF, Young RC, et al. Randomized phase Ⅲ trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2006, 102(3): 432-439. DOI: 10.1016/j.ygyno.2006.06.013.
[27]	Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 116(3): 301-306. DOI: 10.1016/j.ygyno.2009.10.073.
[28]	FIGO Committee on Gynecologic Oncology, Prat J. FIGO′s staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication[J]. J Gynecol Oncol, 2015, 26(2): 87-89. DOI: 10.3802/jgo.2015.26.2.87.
[29]	Deborah K, Ronald D, Jamie N, et al. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 3. 2019)[EB/OL]. (2019-11-26) [2020-01-04]. URL
[30]	Kleppe M, van der Aa MA, Van Gorp T, et al. The impact of lymph node dissection and adjuvant chemotherapy on survival: a nationwide cohort study of patients with clinical early-stage ovarian cancer[J]. Eur J Cancer, 2016, 66: 83-90. DOI: 10.1016/j.ejca.2016.07.015.
[31]	Matulonis UA, Sood AK, Fallowfield L, et al. Ovarian cancer[J]. Nat Rev Dis Primers, 2016, 2: 16061. DOI: 10.1038/nrdp.2016.61.
[32]	Desantis CE, Siegel RL, Sauer AG, et al. Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities[J]. CA Cancer J Clin, 2016, 66(4): 290-308. DOI: 10.3322/caac.21340.
[33]	Zsiros E, Tanyi J, Balint K, et al. Immunotherapy for ovarian cancer: recent advances and perspectives[J]. Curr Opin Oncol, 2014, 26(5): 492-500. DOI: 10.1097/CCO.0000000000000111，PMID: 25036883.
[34]	唐英，李均，徐凡，等. 单核细胞与淋巴细胞比值及其与上皮性卵巢癌患者预后的关系 [J/CD] . 中华妇幼临床医学杂志(电子版)，2017，13(5): 532-538. DOI: 10.3877/cma.j.issn.1673-5250.2017.05.006.

[1]	卢菊, 赵胜, 范建华, 高艳多. 探讨IOTA、GI-RADS及O-RADS在附件肿瘤良恶性鉴别诊断中的价值[J/OL]. 中华医学超声杂志（电子版）, 2024, 21(05): 484-490.
[2]	张舒沁, 陈练. 产后宫腔内妊娠物残留的诊断和临床处理[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 493-497.
[3]	石皆春, 范子玉, 邢燕. 不同筛查方法预警宫颈原位腺癌的效能[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 575-581.
[4]	唐丹, 姚晓曦, 杨博文, 薛绍龙, 李梦瑶, 韦柳杏, 郄明蓉. 双肾上腺皮质激素样激酶1对子宫内膜样腺癌患者临床特征的影响[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 582-590.
[5]	魏艺, 周羽西, 杨烨, 凌秀凤, 赵纯. 微小RNA对子宫内膜容受性影响的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 266-270.
[6]	林琳, 田思萌, 于永华, 徐飞飞, 黄明莉. 干细胞及其外泌体治疗宫腔黏连的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 271-275.
[7]	李欣, 魏艺, 张娟, 张娟娟, 凌秀凤, 赵纯, 张媔秋. 高龄女性冻胚移植周期临床妊娠结局的影响因素分析[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(03): 276-283.
[8]	杨琳, 尹如铁. 外阴白色病变病因研究及治疗现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 157-165.
[9]	高伟聪, 李丽, 张中华, 朱向辉, 刘素巧. 宫颈癌患者糖调节受损对改良根治术后2年内复发的影响作用[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(02): 231-237.
[10]	何欣林, 阎昊铮, 赵亦非, 江彩霞, 李征宇. 新辅助化疗联合间歇性肿瘤细胞减灭术对上皮性卵巢癌患者预后及血清学与影像学指标对患者预后的预测价值[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(01): 47-57.
[11]	王丽, 王月莺, 周芬, 郭宇堃, 魏丽娜. 促性腺激素释放激素拮抗剂对子宫内膜容受性影响的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2023, 19(06): 629-635.
[12]	刘庭秀, 刘新敏, 刘莹, 隋娟, 武宇, 赵瑜敬, 毕红, 孙雪梅, 范秀华. 腹壁整形术后腹腔镜新脐入路治疗卵巢肿物的安全性探讨[J/OL]. 中华腔镜外科杂志(电子版), 2024, 17(03): 189-192.
[13]	雷永琪, 刘新阳, 杨黎渝, 铁学宏, 俞星新, 耿志达, 刘雨, 陈政良, 惠鹏, 梁英健. 肝脏血管周上皮样细胞肿瘤合并贫血一例并文献复习[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 710-718.
[14]	杨麦青, 张云香. 胃癌化疗后浆膜腔大B细胞淋巴瘤一例报道并文献复习[J/OL]. 中华诊断学电子杂志, 2024, 12(03): 183-187.
[15]	张允耀, 王静, 范爱娟, 牟海萍. 超声诊断卵巢交界性肿瘤临床价值的荟萃分析[J/OL]. 中华诊断学电子杂志, 2024, 12(02): 85-89.

阅读次数

全文

摘要

选择文件类型/文献管理软件名称

选择包含的内容

Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

Current chemotherapy research status and consideration of early-stage epithelial ovarian cancer